Rational discovery of dengue type 2 non-competitive inhibitors

Chemical Biology and Drug Design

Volumn 82, Issue 1, 2013, Pages 1-11

  Heh, Choon H ^a   Othman, Rozana ^a   Buckle, Michael J C ^a   Sharifuddin, Yusrizam ^a,b   Yusof, Rohana ^a   Rahman, Noorsaadah A ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

AutoDock virtual screening; DEN 2; Dengue virus type 2; NS2B NS3; Protease assay; Rational drug discovery; Small compounds

Indexed keywords

2 (2,3 DIHYDRO 1,4 BENZODIOXIN 6 YL) 3,4 DIHYDRO 2H 1 BENZOPYRAN 4 ONE; 2 [4 (DIMETHYLAMINO)PHENYL] 5,7 DIMETHYYL 3,4 DIHYDRO 2H 1 BENZOPYRAN 4 ONE; 2 PHENYL 6 (1H 1,2,3,4 TETRAZZOL 5 YL) 4H CHROMEN 4 ONE; 6 PHENYL 6A,12A DIHYDRO 6H,7H CHROMENO [4,3 B]CHROMENE; ANTIVIRUS AGENT; CARDAMONIN; FLAVANONE; NONSTRUCTURAL PROTEIN 2B NONSTRUCTURAL PROTEIN 3 PROTEASE; NONSTRUCTURAL PROTEIN 2B NONSTRUCTURAL PROTEIN 3 PROTEASE INHIBITOR; PINOSTROBIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DENGUE VIRUS 2; ENZYME INHIBITION; IN VITRO STUDY; MOLECULAR DOCKING; PRIORITY JOURNAL; PROTEIN DEGRADATION;

ALLOSTERIC REGULATION; BINDING SITES; DENGUE; DENGUE VIRUS; FLAVONES; HUMANS; KINETICS; MOLECULAR DOCKING SIMULATION; PROTEASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; RNA HELICASES; SERINE ENDOPEPTIDASES; TETRAZOLES; THERMODYNAMICS; VIRAL NONSTRUCTURAL PROTEINS;

DENGUE VIRUS TYPE 2; WEST NILE VIRUS;

EID: 84879541677     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/cbdd.12122     Document Type: Article

References (51)

1. Gubler D.J. (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev;11:480-496.
2. Guha-Sapir D., Schimmer B. (2005) Dengue fever: new paradigms for a changing epidemiology. Emerg Themes Epidemiol;2:1.
3. Frecer V., Miertus S. (2010) Design, structure-based focusing and in silico screening of combinatorial library of peptidomimetic inhibitors of dengue virus NS2B-NS3 protease. J Comput Aided Mol Des;24:195-212.
4. Frimayanti N., Chee C.F., Zain S.M., Rahman N.A. (2011) Design of new competitive dengue ns2b/ns3 protease inhibitors-a computational approach. Int J Mol Sci;12:1089-1100.
5. Hrobowski Y.M., Garry R.F., Michael S.F. (2005) Peptide inhibitors of dengue virus and West Nile virus infectivity. Virol J;2:49.
6. Kiat T.S., Pippen R., Yusof R., Ibrahim H., Khalid N., Rahman N.A. (2006) Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease. Bioorg Med Chem Lett;16:3337-3340.
7. Lee Y.K., Tan S.K., Habibah A.W., Rohana Y., Noorsaadah A.R. (2007) Nonsubstrate based inhibitors of dengue virus serine protease: a molecular docking approach to study binding interactions between protease and inhibitors. Asia Pac J Mol Biol Biotechnol;15:53-59.
8. Lescar J., Luo D., Xu T., Sampath A., Lim S.P., Canard B., Vasudevan S.G. (2008) Towards the design of antiviral inhibitors against flaviviruses: the case for the multifunctional NS3 protein from dengue virus as a target. Antiviral Res;80:94-101.
9. Leung D., Schroder K., White H., Fang N.X., Stoermer M.J., Abbenante G., Martin J.L., Young P.R., Fairlie D.P. (2001) Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors. J Biol Chem;276:45762-45771.
10. Othman R., Kiat T.S., Khalid N., Yusof R., Newhouse E.I., Newhouse J.S., Alam M., Rahman N.A. (2008) Docking of noncompetitive inhibitors into dengue virus type 2 protease: understanding the interactions with allosteric binding sites. J Chem Inf Model;48:1582-1591.
11. Whitby K., Pierson T.C., Geiss B., Lane K., Engle M., Zhou Y., Doms R.W., Diamond M.S. (2005) Castanospermine, a potent inhibitor of dengue virus infection in vitro and in vivo. J Virol;79:8698-8706.
12. Yin Z., Patel S.J., Wang W.L., Chan W.L., Ranga Rao K.R., Wang G., Ngew X., Patel V., Beer D., Knox J.E., Ma N.L., Ehrhardt C., Lim S.P., Vasudevan S.G., Keller T.H. (2006) Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett;16:40-43.
13. Yin Z., Patel S.J., Wang W.L., Wang G., Chan W.L., Rao K.R., Alam J., Jeyaraj D.A., Ngew X., Patel V., Beer D., Lim S.P., Vasudevan S.G., Keller T.H. (2006) Peptide inhibitors of dengue virus NS3 protease. Part 1: warhead. Bioorg Med Chem Lett;16:36-39.
14. Muhamad M., Kee L.Y., Rahman N.A., Yusof R. (2010) Antiviral actions of flavanoid-derived compounds on dengue virus type-2. Int J Biol Sci;6:294-302.
15. Durbin A.P., Karron R.A., Sun W., Vaughn D.W., Reynolds M.J., Perreault J.R., Thumar B., Men R., Lai C.J., Elkins W.R., Chanock R.M., Murphy B.R., Whitehead S.S. (2001) Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3′-untranslated region. Am J Trop Med Hyg;65:405-413.
16. Durbin A.P., Whitehead S.S., McArthur J., Perreault J.R., Blaney J.E. Jr, Thumar B., Murphy B.R., Karron R.A. (2005) rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis;191:710-718.
17. Edelman R. (2007) Dengue vaccines approach the finish line. Clin Infect Dis;45(Suppl 1):S56-S60.
18. Hanley K.A., Manlucu L.R., Manipon G.G., Hanson C.T., Whitehead S.S., Murphy B.R., Blaney J.E. Jr. (2004) Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccines;22:3440-3448.
19. McKee K.T. Jr, Bancroft W.H., Eckels K.H., Redfield R.R., Summers P.L., Russell P.K. (1987) Lack of attenuation of a candidate dengue 1 vaccine (45AZ5) in human volunteers. Am J Trop Med Hyg;36:435-442.
20. Robert Putnak J., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., Bignami G. et al. (2005) An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccines;23:4442-4452.
21. Whitehead S.S., Falgout B., Hanley K.A., Blaney J.E. Jr, Markoff L., Murphy B.R. (2003) A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3′ untranslated region is highly attenuated and immunogenic in monkeys. J Virol;77:1653-1657.
22. Gould D.J., Yuill T.M., Moussa M.A., Simasathien P., Rutledge L.C. (1968) An insular outbreak of dengue hemorrhagic fever. 3. Identification of vectors and observations on vector ecology. Am J Trop Med Hyg;17:609-618.
23. Hammon W.M., Rudnick A., Sather G.E. (1960) Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thailand. Science;131:1102-1103.
24. Rosen L., editor. (1983) The Global Importance of Dengue Infection and Disease. Proceedings of the International Conference on DHF. Kuala Lampur, Malaysia: University of Malaysia.
25. Simmons J.S., St. Johns J.H., Reynolds F.H.K. (1931) Experimental studies of dengue. Philipp J Sci;44:1-251.
26. Irie K., Mohan P.M., Sasaguri Y., Putnak R., Padmanabhan R. (1989) Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain). Gene;75:197-211.
27. Falgout B., Pethel M., Zhang Y.M., Lai C.J. (1991) Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins. J Virol;65:2467-2475.
28. Leung J.Y., Pijlman G.P., Kondratieva N., Hyde J., Mackenzie J.M., Khromykh A.A. (2008) Role of nonstructural protein NS2A in flavivirus assembly. J Virol;82:4731-4741.
29. Yusof R., Clum S., Wetzel M., Murthy H.M., Padmanabhan R. (2000) Purified NS2B/NS3 serine protease of dengue virus type 2 exhibits cofactor NS2B dependence for cleavage of substrates with dibasic amino acids in vitro. J Biol Chem;275:9963-9969.
30. Chambers T.J., Weir R.C., Grakoui A., McCourt D.W., Bazan J.F., Fletterick R.J., Rice C.M. (1990) Evidence that the N-terminal domain of nonstructural protein NS3 from yellow fever virus is a serine protease responsible for site-specific cleavages in the viral polyprotein. Proc Natl Acad Sci USA;87:8898-8902.
31. Zhang L., Padmanabhan R. (1993) Role of protein conformation in the processing of dengue virus type 2 nonstructural polyprotein precursor. Gene;129:197-205.
32. Lindenbach B.D., Thiel H.J., Rice C.M. (2007) Flaviviridae: the viruses and their replication. In: Knipe D.M., Howley P.M., editors. Fields Virology, 5th edn. Philadelphia: Lippincott-Raven Publishers; p. 1101-1152.
33. Erbel P., Schiering N., D'Arcy A., Renatus M., Kroemer M., Lim S.P., Yin Z., Keller T.H., Vasudevan S.G., Hommel U. (2006) Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus. Nat Struct Mol Biol;13:372-373.
34. Aleshin A.E., Shiryaev S.A., Strongin A.Y., Liddington R.C. (2007) Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold. Protein Sci;16:795-806.
35. Robin G., Chappell K., Stoermer M.J., Hu S.H., Young P.R., Fairlie D.P., Martin J.L. (2009) Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation. J Mol Biol;385:1568-1577.
36. Chandramouli S., Joseph J.S., Daudenarde S., Gatchalian J., Cornillez-Ty C., Kuhn P. (2010) Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family. J Virol;84:3059-3067.
37. Noble C.G., Seh C.C., Chao A.T., Shi P.Y. (2012) Ligand-bound structures of the dengue virus protease reveal the active conformation. J Virol;86:438-446.
38. Yan Y., Li Y., Munshi S., Sardana V., Cole J.L., Sardana M., Steinkuehler C., Tomei L., De Francesco R., Kuo L.C., Chen Z. (1998) Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 A resolution structure in a hexagonal crystal form. Protein Sci;7:837-847.
39. Lee Y.K., Rozana O., Habibah A.W., Rohana Y., Noorsaadah A.R. (2006) A revisit into the DEN2 NS2B/NS3 Virus Protease Homology Model: structural verification and comparison with crystal structure of HCV NS3/4A and DEN2 NS3. Malays J Sci;25:15-22.
40. Wichapong K., Pianwanit S., Sippl W., Kokpol S. (2010) Homology modeling and molecular dynamics simulations of dengue virus NS2B/NS3 protease: insight into molecular interaction. J Mol Recognit;23:283-300.
41. Huey R., Morris G.M., Olson A.J., Goodsell D.S. (2007) A semiempirical free energy force field with charge-based desolvation. J Comput Chem;28:1145-1152.
42. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem;19:1639-1662.
43. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem;30:2785-2791.
44. Irwin J.J., Shoichet B.K. (2005) ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model;45:177-182.
45. Sali A., Blundell T.L. (1993) Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol;234:779-815.
46. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr;26:283-291.
47. Luthy R., Bowie J.U., Eisenberg D. (1992) Assessment of protein models with three-dimensional profiles. Nature;356:83-85.
48. Wallace A.C., Laskowski R.A., Thornton J.M. (1995) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng;8:127-134.
49. Tomlinson S.M., Watowich S.J. (2008) Substrate inhibition kinetic model for West Nile virus NS2B-NS3 protease. Biochemistry;47:11763-11770.
50. Copeland R.A. (2002) Reversible Inhibitors, in Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis, 2nd edn. New York: John Wiley & Sons Inc. p. 266-304.
51. Geiss B.J., Thompson A.A., Andrews A.J., Sons R.L., Gari H.H., Keenan S.M., Peersen O.B. (2009) Analysis of flavivirus NS5 methyltransferase cap binding. J Mol Biol;385:1643-1654.